Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Flaherty, Keith
Item TypeName
Academic Article Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Academic Article Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Academic Article VEGFR-targeted therapy.
Academic Article Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
Academic Article Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Academic Article Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Academic Article Resistance to BRAF-targeted therapy in melanoma.
Academic Article An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.
Academic Article BRAF, a target in melanoma: implications for solid tumor drug development.
Academic Article COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Academic Article CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Academic Article Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Academic Article Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Academic Article Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Academic Article Targeting the RAS pathway in melanoma.
Academic Article BRAF inhibitors and melanoma.
Academic Article Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
Academic Article Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.
Academic Article Is it good or bad to find a BRAF mutation?
Academic Article Improved survival with MEK inhibition in BRAF-mutated melanoma.
Academic Article Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Academic Article BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Academic Article RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Academic Article CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Academic Article Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
Academic Article MEK and RAF inhibitors for BRAF-mutated cancers.
Academic Article RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Academic Article Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Academic Article Hyperspectral imaging: a non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor.
Academic Article The future of tyrosine kinase inhibitors: single agent or combination?
Academic Article Biological challenges of BRAF inhibitor therapy.
Academic Article Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
Concept Protein Kinase Inhibitors
Academic Article MAP kinase signaling and inhibition in melanoma.
Academic Article BRAF in melanoma: current strategies and future directions.
Academic Article TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Academic Article MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Academic Article A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
Academic Article Major therapeutic developments and current challenges in advanced melanoma.
Academic Article Cyclin-dependent kinases as therapeutic targets in melanoma.
Academic Article Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
Academic Article Genetic alterations and personalized medicine in melanoma: progress and future prospects.
Academic Article Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
Academic Article Pathways and therapeutic targets in melanoma.
Academic Article PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
Academic Article A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Academic Article Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Academic Article The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFa.
Academic Article Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Academic Article Improved overall survival in melanoma with combined dabrafenib and trametinib.
Academic Article Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Academic Article EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.
Academic Article Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.
Academic Article Effectively targeting CRAF: rational serendipity targeting SRC?
Academic Article The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Academic Article Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.
Academic Article YAP in MAPK pathway targeted therapy resistance.
Academic Article Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.
Academic Article Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
Academic Article Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Academic Article BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
Academic Article Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.
Academic Article Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Academic Article Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Academic Article Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Academic Article Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Academic Article Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Academic Article Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance.
Academic Article Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Academic Article A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors.
Academic Article Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Academic Article Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
Academic Article MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Academic Article MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Academic Article Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Academic Article PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.
Academic Article Tissue-Agnostic Drug Development.
Academic Article An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.
Academic Article Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.
Academic Article A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Academic Article Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
Academic Article BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Academic Article Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Academic Article Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Academic Article PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Academic Article First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Academic Article Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Academic Article Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Academic Article Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Academic Article Toward Minimal Residual Disease-Directed Therapy in Melanoma.
Academic Article Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Academic Article A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.
Academic Article A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Academic Article ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Academic Article A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.
Academic Article Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Academic Article Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Search Criteria
  • Protein Kinase Inhibitors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.